Distinct plasma immune signatures in ME/CFS are present early in the course of illness

Science Advances

Volumn 1, Issue 1, 2015, Pages

  Hornig, Mady ^a   Montoya, José G ^b   Klimas, Nancy G ^c,d   Levine, Susan ^e   Felsenstein, Donna ^f   Bateman, Lucinda ^g   Peterson, Daniel L ^h   Gottschalk, C Gunnar ^h   Schultz, Andrew F ^a   Che, Xiaoyu ^a   Eddy, Meredith L ^a   Komaroff, Anthony L ⁱ   Lipkin, W Ian ^a,j  

^a Department of Medicine   (United States)

^b STANFORD UNIVERSITY   (United States)

^c affiliation with Nova Southeastern College of Osteopathic Medicine   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Levine Clinic   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g Fatigue Consultation Clinic   (United States)

^h Sierra Internal Medicine Associates   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j Columbia University ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; DIAGNOSIS;

ANTI-INFLAMMATORIES; EARLY DIAGNOSIS; HEALTHY CONTROLS; IMMUNOPATHOLOGY; LABORATORY METHODS; LABORATORY TEST; REGULATORY NETWORK; SAMPLE COLLECTION;

DISEASES;

EID: 85026347818     PISSN: None     EISSN: 23752548     Source Type: Journal    
DOI: 10.1126/sciadv.1400121     Document Type: Article

References (72)

1. K. G. Brurberg, M. S. Fonhus, L. Larun, S. Flottorp, K. Malterud, Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review. BMJ Open 4, e003973 (2014).
2. B.M. Carruthers, A. K. Jain, K. L. DeMeirleir, D. L. Peterson, N. G. Klimas, A. M. Lerner, A. C. Bested, P. Flor-Henry, P. Joshi, A. C. P. Powles, J. A. Sherkey, M. I. van de Sande, Myalgic encephalomyelitis/ chronic fatigue syndrome: Clinical working case definition, diagnostic and treatments protocols. J. Chr. Fatigue Synd. 11, 7-115 (2003).
3. L. A. Jason, M. Evans, N. Porter, M. Brown, A. Brown, J. Hunnell, V. Anderson, A. Lerch, K. DeMeirleir, F. Friedberg, The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am. J. Biochem. Biotechnol. 6, 120-135 (2010).
4. E. M. Tan, K. Sugiura, S. Gupta, The case definition of chronic fatigue syndrome. J. Clin. Immunol. 22, 8-12 (2002).
5. M. K. Ravindran, Y. Zheng, C. Timbol, S. J. Merck, J. N. Baraniuk, Migraine headaches in chronic fatigue syndrome (CFS): Comparison of two prospective cross-sectional studies. BMC Neurol. 11, 30 (2011).
6. C. M. Chang, J. L. Warren, E. A. Engels, Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 118, 5929-5936 (2012).
7. E. W. Brenu, M. L. van Driel, D. R. Staines, K. J. Ashton, S. B. Ramos, J. Keane, N. G. Klimas, S. M. Marshall-Gradisnik, Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J. Transl. Med. 9, 81 (2011).
8. H. J. Cho, A. Skowera, A. Cleare, S. Wessely, Chronic fatigue syndrome: An update focusing on phenomenology and pathophysiology. Curr. Opin. Psychiatry 19, 67-73 (2006).
9. M. Lyall, M. Peakman, S. Wessely, A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J. Psychosom. Res. 55, 79-90 (2003).
10. J. Nijs, A. Nees, L. Paul, M. De Kooning, K. Ickmans, M. Meeus, J. Van Oosterwijck, Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: A systematic literature review. Exerc. Immunol. Rev. 20, 94-116 (2014).
11. H. J. Alter, J. A. Mikovits, W. M. Switzer, F. W. Ruscetti, S. C. Lo, N. Klimas, A. L. Komaroff, J. G. Montoya, L. Bateman, S. Levine, D. Peterson, B. Levin, M. R. Hanson, A. Genfi, M. Bhat, H. Zheng, R. Wang, B. Li, G. C. Hung, L. L. Lee, S. Sameroff, W. Heneine, J. Coffin, M. Hornig, W. I. Lipkin, A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio 3, e00266-12 (2012).
12. J. Kaiser, Family puts $10 million into chronic fatigue research. ScienceInsider, 19 September 2011. 13. E. G. Lattie, M. H. Antoni, M. A. Fletcher, S. Czaja, D. Perdomo, A. Sala, S. Nair, S. H. Fu, F. J. Penedo, N. Klimas, Beyond myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptom severity: Stress management skills are related to lower illness burden. Fatigue 1 (2013).
13. S. Mia, A. Warnecke, X. M. Zhang, V. Malmstrom, R. A. Harris, An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-b yields a dominant immunosuppressive phenotype. Scand. J. Immunol. 79, 305-314 (2014).
14. L. Darwich, G. Coma, R. Pena, R. Bellido, E. J. Blanco, J. A. Este, F. E. Borras, B. Clotet, L. Ruiz, A. Rosell, F. Andreo, R. M. Parkhouse, M. Bofill, Secretion of interferon-g by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 126, 386-393 (2009).
15. C. M. Robinson, D. O'Dee, T. Hamilton, G. J. Nau, Cytokines involved in interferon-g production by human macrophages. J. Innate Immun. 2, 56-65 (2010).
16. R. De Simone, G. Levi, F. Aloisi, Interferon g gene expression in rat central nervous system glial cells. Cytokine 10, 418-422 (1998).
17. J. Kawanokuchi, T. Mizuno, H. Takeuchi, H. Kato, J. Wang, N. Mitsuma, A. Suzumura, Production of interferon-g by microglia. Mult. Scler. 12, 558-564 (2006).
18. J. Makela, R. Koivuniemi, L. Korhonen, D. Lindholm, Interferon-g produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells. PLOS One 5, e11091 (2010).
19. S. V. Skurkovich, B. Skurkovich, J. A. Kelly, Anticytokine therapy-New approach to the treatment of autoimmune and cytokine-disturbance diseases. Med. Hypotheses 59, 770-780 (2002).
20. J. R. Schoenborn, C. B. Wilson, Regulation of interferon-g during innate and adaptive immune responses. Adv. Immunol. 96, 41-101 (2007).
21. F. Annunziato, C. Romagnani, S. Romagnani, The 3 major types of innate and adaptive cellmediated effector immunity. J. Allergy Clin. Immunol. S0091-6749(14)01585-1 (2014).
22. I. J. Elenkov, Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci. 1024, 138-146 (2004).
23. D. Neu, O. Mairesse, X. Montana, M. Gilson, F. Corazza, N. Lefevre, P. Linkowski, O. Le Bon, P. Verbanck, Dimensions of pure chronic fatigue: Psychophysical, cognitive and biological correlates in the chronic fatigue syndrome. Eur. J. Appl. Physiol. 114, 1841-1851 (2014).
24. G. Broderick, J. Fuite, A. Kreitz, S. D. Vernon, N. Klimas, M. A. Fletcher, A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav. Immun. 24, 1209-1217 (2010).
25. M. A. Fletcher, X. R. Zeng, Z. Barnes, S. Levis, N. G. Klimas, Plasma cytokines in women with chronic fatigue syndrome. J. Transl. Med. 7, 96 (2009).
26. A. L. Smylie, G. Broderick, H. Fernandes, S. Razdan, Z. Barnes, F. Collado, C. Sol, M. A. Fletcher, N. Klimas, A comparison of sex-specific immune signatures in Gulf War illness and chronic fatigue syndrome. BMC Immunol. 14, 29 (2013).
27. M. N. Garcia, A. M. Hause, C. M. Walker, J. S. Orange, R. Hasbun, K. O. Murray, Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines. Viral Immunol. 27, 327-333 (2014).
28. B. Piraino, U. Vollmer-Conna, A. R. Lloyd, Genetic associations of fatigue and other symptom domains of the acute sickness response to infection. Brain Behav. Immun. 26, 552-558 (2012).
29. A. H. Miller, E. Haroon, C. L. Raison, J. C. Felger, Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress. Anxiety 30, 297-306 (2013).
30. A. M. Myint, Y. K. Kim, Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 48, 304-313 (2014).
31. R. Bellmann-Weiler, K. Schroecksnadel, C. Holzer, C. Larcher, D. Fuchs, G. Weiss, IFN-gamma mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. J. Affect. Disord. 108, 171-176 (2008).
32. L. Tan, J. T. Yu, L. Tan, The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations. J. Neurol. Sci. 323, 1-8 (2012).
33. A. M. Myint, M. J. Schwarz, N. Muller, The role of the kynurenine metabolism in major depression. J. Neural Transm. 119, 245-251 (2012).
34. G. Anderson, M. Berk, M. Maes, Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr. Scand. 129, 83-97 (2014).
35. M. Maes, I. Mihaylova, M. D. Ruyter, M. Kubera, E. Bosmans, The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): Relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol. Lett. 28, 826-831 (2007).
36. A. Durandy, G. De Saint Basile, B. Lisowska-Grospierre, J. F. Gauchat, M. Forveille, R. A. Kroczek, J. Y. Bonnefoy, A. Fischer, Undetectable CD40 ligand expression on T cells and low B cell responses to CD40 binding agonists in human newborns. J. Immunol. 154, 1560-1568 (1995).
37. M. S. Elkind, J. M. Luna, C. S. Coffey, L. A. McClure, K. M. Liu, S. Spitalnik, M. C. Paik, A. Roldan, C. White, R. Hart, O. Benavente, The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): Inflammatory biomarkers as risk predictors after lacunar stroke. Int. J. Stroke 5, 117-125 (2010).
38. J. Ross, S. Sharma, J. Winston, M. Nunez, G. Bottini, M. Franceschi, E. Scarpini, E. Frigerio, F. Fiorentini, M. Fernandez, S. Sivilia, L. Giardino, L. Calza, D. Norris, H. Cicirello, D. Casula, B. P. Imbimbo, CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: A 12-week, double-blind, placebo-controlled study. Curr. Alzheimer Res. 10, 742-753 (2013).
39. P. Buchhave, S. Janciauskiene, H. Zetterberg, K. Blennow, L. Minthon, O. Hansson, Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neurosci. Lett. 450, 56-59 (2009).
40. S. Bishu, D. Madhavan, P. Perez, L. Civitello, S. Liu, M. Fessler, S. M. Holland, A. Jain, M. Pao, CD40 ligand deficiency: Neurologic sequelae with radiographic correlation. Pediatr. Neurol. 41, 419-427 (2009).
41. A. Festa, S. M. Haffner, L. E. Wagenknecht, C. Lorenzo, A. J. Hanley, Longitudinal decline of b-cell function: Comparison of a direct method vs a fasting surrogate measure: The Insulin Resistance Atherosclerosis Study. J. Clin. Endocrinol. Metab. 98, 4152-4159 (2013).
42. D. T. Utzschneider, A. Legat, S. A. Fuertes Marraco, L. Carrie, I. Luescher, D. E. Speiser, D. Zehn, T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14, 603-610 (2013).
43. S. Ferrando-Martinez, E. Ruiz-Mateos, M. C. Romero-Sanchez, M. A. Munoz-Fernandez, P. Viciana, M. Genebat, M. Leal, HIV infection-related premature immunosenescence: High rates of immune exhaustion after short time of infection. Curr. HIV Res. 9, 289-294 (2011).
44. L. Golden-Mason, B. Palmer, J. Klarquist, J. A. Mengshol, N. Castelblanco, H. R. Rosen, Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81, 9249-9258 (2007).
45. S. Gupta, B. Vayuvegula, A comprehensive immunological analysis in chronic fatigue syndrome. Scand. J. Immunol. 33, 319-327 (1991).
46. U. Tirelli, G. Marotta, S. Improta, A. Pinto, Immunological abnormalities in patients with chronic fatigue syndrome. Scand. J. Immunol. 40, 601-608 (1994).
47. A. T. White, A. R. Light, R. W. Hughen, L. Bateman, T. B. Martins, H. R. Hill, K. C. Light, Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 47, 615-624 (2010).
48. R. C. Rickert, J. Jellusova, A. V. Miletic, Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244, 115-133 (2011).
49. M. J. Robertson, R. S. Schacterle, G.A.Mackin, S. N.Wilson, K. L. Bloomingdale, J. Ritz, A. L. Komaroff, Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin. Exp. Immunol. 141, 326-332 (2005).
50. M. Curriu, J. Carrillo, M. Massanella, J. Rigau, J. Alegre, J. Puig, A. M. Garcia-Quintana, J. Castro-Marrero, E. Negredo, B. Clotet, C. Cabrera, J. Blanco, Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J. Transl. Med. 11, 68 (2013).
51. J. J. LaManca, S. A. Sisto, X. D. Zhou, J. E. Ottenweller, S. Cook, A. Peckerman, Q. Zhang, T. N. Denny, W. C. Gause, B. H. Natelson, Immunological response in chronic fatigue syndrome following a graded exercise test to exhaustion. J. Clin. Immunol. 19, 135-142 (1999).
52. G. Morris, M. Maes, Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 11, 205 (2013).
53. O. Fluge, O. Bruland, K. Risa, A. Storstein, E. K. Kristoffersen, D. Sapkota, H. Naess, O. Dahl, H. Nyland, O. Mella, Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS One 6, e26358 (2011).
54. R. Moss-Morris, V. Deary, B. Castell, Chronic fatigue syndrome. Handb. Clin. Neurol. 110, 303-314 (2013).
55. D. B. Fischer, A. H. William, A. C. Strauss, E. R. Unger, L. Jason, G. D. Marshall Jr., J. D. Dimitrakoff, Chronic fatigue syndrome: The current status and future potentials of emerging biomarkers. Fatigue 2, 93-109 (2014).
56. K. O. Murray, M. N. Garcia, M. H. Rahbar, D. Martinez, S. A. Khuwaja, R. R. Arafat, S. Rossmann, Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLOS One 9, e102953 (2014).
57. A. Alberti, L. Chemello, L. Benvegnu, Natural history of hepatitis C. J. Hepatol. 31 (Suppl. 1), 17-24 (1999).
58. A. Khaitan, D. Unutmaz, Revisiting immune exhaustion during HIV infection. Curr. HIV/AIDS Rep. 8, 4-11 (2011).
59. L. B. Dustin, C. M. Rice, Flying under the radar: The immunobiology of hepatitis C. Annu. Rev. Immunol. 25, 71-99 (2007).
60. M. Barathan, K. Gopal, R.Mohamed, R. Ellegard, A. Saeidi, J. Vadivelu, A. W. Ansari,H. A. Rothan, M. Ravishankar Ram, K. Zandi, L. Y. Chang, R. Vignesh, K. F. Che, A. Kamarulzaman, V. Velu, M. Larsson, T. Kamarul, E. M. Shankar, Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis 10.1007/s10495-1084-y (2015).
61. E. M. Smets, B. Garssen, B. Bonke, J. C. De Haes, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315-325 (1995).
62. K. Fukuda, S. E. Straus, I. Hickie, M. C. Sharpe, J. G. Dobbins, A. Komaroff, The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121, 953-959 (1994).
63. P. Wipfler, A. Heikkinen, A. Harrer, G. Pilz, A. Kunz, S. M. Golaszewski, R. Reuss, P. Oschmann, J. Kraus, Circadian rhythmicity of inflammatory serum parameters: A neglected issue in the search of biomarkers in multiple sclerosis. J. Neurol. 260, 221-227 (2013).
64. L. J. Crofford, K. T. Kalogeras, G. Mastorakos, M. A. Magiakou, J. Wells, K. S. Kanik, P. W. Gold, G. P. Chrousos, R. L. Wilder, Circadian relationships between interleukin (IL)-6 and hypothalamicpituitary- adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82, 1279-1283 (1997).
65. T. B. Martins, Development of internal controls for the Luminex instrument as part of a multiplex seven-analyte viral respiratory antibody profile. Clin. Diagn. Lab. Immunol. 9, 41-45 (2002).
66. D. A. Vignali, Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 243, 243-255 (2000).
67. G. E. P. Box, D. R. Cox, An analysis of transformations. J. R. Stat. Soc. Ser. B Stat. Methodol. 26, 211-252 (1964).
68. R. Tibshirani, Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 58, 267-288 (1996).
69. M. Smith, N. Milic-Frayling, B. Shneiderman, E. Mendes Rodrigues, J. Leskovec, C. Dunne. NodeXL: A Free and Open Network Overview, Discovery and Exploration Add-in for Excel 2007/ 2010 (Social Media Research Foundation, Belmont, CA, 2010); www.smrfoundation.org.
70. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289-300 (1995).
71. L. Breiman, J. H. Friedman, R. A. Olshen, C. J. Stone, Classification and Regression Trees (Wadsworth & Brooks/Cole Advanced Books & Software, Monterey, CA, 1984).
72. A. M. Aguilera, M. Escabias, M. J. Valderrama, Using principal components for estimating logistic regression with high-dimensional multicollinear data. Comput. Stat. Data Anal. 50, 1905-1924 (2006).